Key result
Low-dose oral vitamin K lowers INR into the therapeutic range vs placebo in warfarin patients.
Why the study?
Does low dose oral vitamin K lower the INR better than placebo in patients receiving warfarin with an INR between 4.5 and 10.0?
RCT (n=92)
Triple-blind
Allocation concealed
Yes
Does low dose oral vitamin K lower the INR better than placebo in patients receiving warfarin with an INR between 4.5 and 10.0?
Low dose oral vitamin K effectively lowers INR into the therapeutic range in patients with warfarin-associated coagulopathy (INR 4.5-10.0).
Answers are grounded in this paper and cite their sources.
Supports low-dose oral vitamin K for INR 4.5-10 on warfarin; confirms superiority to placebo in RCT.
(2000) Lancet 356, 1551. Crowther MA, Julian J, McCarty D, et al. . Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial. . Nov 4; . : . –3. . [OpenUrl][1][CrossRef][2][PubMed][3][Web of Science][4] QUESTION: In patients who are receiving warfarin and have an international normalised ratio (INR) value between 4.5 and 10.0, does low dose vitamin K lower the INR better than placebo? Randomised (allocation concealed*), blinded {patients, clinicians, and outcome assessors}†,* placebo controlled trial with 3 months of follow up. 5 thromboembolism services at teaching hospitals in London and Hamilton, Ontario, Canada. 92 patients (mean age 65 y, 53% women) who were receiving warfarin and had an INR value between 4.5 and 10.0. Exclusion criteria were INR determined >12 hours before screening, life expectancy <10 days, need for immediate normalisation of INR, severe liver disease, major bleeding in the previous month, allergy to vitamin K, bleeding diathesis or thrombolytic treatment within 48 hours … [1]: {openurl}?query=rft.jtitle%253DLancet%26rft.stitle%253DLancet%26rft.aulast%253DCrowther%26rft.auinit1%253DM.%2BA.%26rft.volume%253D356%26rft.issue%253D9241%26rft.spage%253D1551%26rft.epage%253D1553%26rft.atitle%253DTreatment%2Bof%2Bwarfarin-associated%2Bcoagulopathy%2Bwith%2Boral%2Bvitamin%2BK%253A%2Ba%2Brandomised%2Bcontrolled%2Btrial.%26rft_id%253Dinfo%253Adoi%252F10.1016%252FS0140-6736%252800%252903125-1%26rft_id%253Dinfo%253Apmid%252F11075768%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx [2]: /lookup/external-ref?access_num=10.1016/S0140-6736(00)03125-1&link_type=DOI [3]: /lookup/external-ref?access_num=11075768&link_type=MED&atom=%2Febmed%2F6%2F4%2F115.atom [4]: /lookup/external-ref?access_num=000165134500010&link_type=ISI
No takes yet. Share an insight, caveat, or question.
Brian P. Schmitt (2001) conducted an RCT in Warfarin-associated coagulopathy (n=92). Oral vitamin K vs. Placebo was evaluated on Lowering the INR into the therapeutic range. Low dose oral vitamin K lowered the international normalised ratio into the therapeutic range in patients receiving warfarin.
Synapse has enriched 10 related papers. Consider them for comparative context: